The high price of innovation: addressing financial toxicity and healthcare inequity in gynecological malignancies

Over the past decade, gynecological oncology has transitioned into an era of precision medicine, immune-targeted therapies, minimally invasive robotic surgery, and advanced radiotherapeutic modalities. While these innovations have extended survival outcomes, their rapid integration has highlighted a major systemic burden: prohibitive care costs. Originally conceptualized by Zafar et al. (1) to describe the material distress and psychological burden patients face during cancer care, "financial toxicity" (FT) is now recognized as a structural barrier to equitable health outcomes. Current evidence indicates that up to 50% of patients with gynecological malignancies experience substantial FT (2), which correlates with compromised quality of life, treatment non-adherence, and inferior overall survival. Moreover, in low-and middle-income countries (LMICs), economic vulnerabilities are widespread across general cancer care populations, with systematic reviews reporting an overall objective FT prevalence reaching 56.96% (3).As healthcare clinicians witnessing these shifting oncological paradigms, we must evaluate the broader socioeconomic implications of technical progress. Clinical advances remain suboptimally realized if treatment access is restricted by socioeconomic geography. The international oncology community-including clinicians, researchers, and public health decision-makers-must work collaboratively toward balanced frameworks that align scientific innovation with sustainable, globally scalable patient accessibility.The transition from traditional morphology-based diagnostics to molecularly driven classification has introduced complex resource demands within the pathology laboratory. Modern practice guidelines, such as the ESMO/ESGO/ESP recommendations for endometrial carcinoma, incorporate proactive molecular workups involving immunohistochemistry (IHC) for mismatch repair (MMR) proteins, p53 expression, estrogen receptor status, and sequencing of the POLE exonuclease domain (4). While these diagnostic algorithms refine risk stratification and guide targeted therapies, economic modeling studies demonstrate that comprehensive molecular profiling carries substantial upfront equipment and operational expenses (5). In resource-limited settings, high platform costs create financial hurdles that may restrict advanced molecular diagnostics to specialized academic centers, complicating the routine delivery of risk-stratified care.Importantly, global consensus bodies have actively recognized these regional implementation challenges. While early guidelines mandated complex diagnostic tiers, recent international initiatives-such as the FIGO 2023 staging system (6,7) and the IGCS 2026 consensus recommendations (8), explicitly incorporate pragmatic, stepwise, or selective molecular testing algorithms tailored for lower-resource health systems. These adaptive frameworks acknowledge that resource availability varies across global settings and encourage diagnostic flexibility to ensure equitable risk stratification (9).To address diagnostic infrastructure bottlenecks, pragmatic and cost-effective methodologies are being validated internationally. Targeted Sanger sequencing of the POLE exonuclease domain offers a reliable, accessible alternative to comprehensive next-generation sequencing (NGS) panels for detecting clinically relevant hotspot mutations, as demonstrated in recent studies across varied health systems (10,11). Supporting adaptive diagnostic pathways within clinical guidelines helps bridge implementation gaps, ensuring that resource-constrained health systems can deliver equitable risk-stratified patient care.The development of targeted systemic therapeutics, including poly (ADP-ribose) polymerase (PARP) inhibitors, antibody-drug conjugates (ADCs), and targeted immunotherapies, has transformed management paradigms for gynecological cancers. However, these novel modalities present significant affordability hurdles across different healthcare structures. In high-income nations, out-of-pocket drug costs and reimbursement thresholds frequently impose substantial personal financial strain, as captured by standardized metrics such as the COST tool (12). In LMICs, where public health coverage for specialized targeted agents may be limited, access barriers remain particularly acute.Beyond direct drug acquisition costs, indirect systemic expenses compound patient financial burdens. Standard safety monitoring and management of immune-related adverse events during targeted therapy and immunotherapy regimens-such as routine endocrine or cardiac biomarker assays-can generate recurring out-of-pocket costs, adding secondary financial distress during prolonged therapeutic courses (13,14).The broader economic impact of cancer treatment extends directly to families and informal caregivers. Studies indicate that a significant proportion of caregivers experience moderate-tosevere financial toxicity, frequently relying on personal savings or asset liquidations to maintain treatment continuity (15). This economic vulnerability is especially pronounced among younger patients and lower-income households (16).Addressing affordability challenges requires a multi-faceted approach. To improve short-term access in resource-limited settings, multinational pharmaceutical sponsors have established compassionate use and patient assistance access programs. While these corporate-sponsored initiatives provide valuable temporary relief for selected cohorts of uninsured or low-income patients, they represent palliative coverage tools rather than permanent structural solutions. Sustainable healthcare equity requires long-term public policy mechanisms, including valuebased pricing and expanded public coverage frameworks.The modernization of surgical and radiotherapeutic modalities reflects similar economic and distribution challenges seen in targeted systemic therapies. Robot-assisted surgery offers established clinical advanta